363 related articles for article (PubMed ID: 32529183)
1. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis.
Wang GY; Rayner SL; Chung R; Shi BY; Liang XJ
Mater Today Bio; 2020 Mar; 6():100055. PubMed ID: 32529183
[TBL] [Abstract][Full Text] [Related]
2. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
[TBL] [Abstract][Full Text] [Related]
3. Altered blood-brain barrier and blood-spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety.
Pan Y; Nicolazzo JA
Br J Pharmacol; 2022 Jun; 179(11):2577-2588. PubMed ID: 35048358
[TBL] [Abstract][Full Text] [Related]
4. Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis.
Mirian A; Moszczynski A; Soleimani S; Aubert I; Zinman L; Abrahao A
Front Cell Neurosci; 2022; 16():851563. PubMed ID: 35431812
[TBL] [Abstract][Full Text] [Related]
5. ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis.
Jablonski M; Miller DS; Pasinelli P; Trotti D
Brain Res; 2015 May; 1607():1-14. PubMed ID: 25175835
[TBL] [Abstract][Full Text] [Related]
6. Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?
Alarcan H; Al Ojaimi Y; Lanznaster D; Escoffre JM; Corcia P; Vourc'h P; Andres CR; Veyrat-Durebex C; Blasco H
J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887567
[TBL] [Abstract][Full Text] [Related]
7. Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS.
Waters S; Swanson MEV; Dieriks BV; Zhang YB; Grimsey NL; Murray HC; Turner C; Waldvogel HJ; Faull RLM; An J; Bowser R; Curtis MA; Dragunow M; Scotter E
Acta Neuropathol Commun; 2021 Aug; 9(1):144. PubMed ID: 34446086
[TBL] [Abstract][Full Text] [Related]
8. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis.
Winkler EA; Sengillo JD; Sullivan JS; Henkel JS; Appel SH; Zlokovic BV
Acta Neuropathol; 2013 Jan; 125(1):111-20. PubMed ID: 22941226
[TBL] [Abstract][Full Text] [Related]
9. Selective induction of P-glycoprotein at the CNS barriers during symptomatic stage of an ALS animal model.
Chan GN; Evans RA; Banks DB; Mesev EV; Miller DS; Cannon RE
Neurosci Lett; 2017 Feb; 639():103-113. PubMed ID: 28011392
[TBL] [Abstract][Full Text] [Related]
10. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
11. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS.
Suzuki M; McHugh J; Tork C; Shelley B; Klein SM; Aebischer P; Svendsen CN
PLoS One; 2007 Aug; 2(8):e689. PubMed ID: 17668067
[TBL] [Abstract][Full Text] [Related]
12. Amyotrophic lateral sclerosis: a neurovascular disease.
Garbuzova-Davis S; Rodrigues MC; Hernandez-Ontiveros DG; Louis MK; Willing AE; Borlongan CV; Sanberg PR
Brain Res; 2011 Jun; 1398():113-25. PubMed ID: 21632035
[TBL] [Abstract][Full Text] [Related]
13. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
Deeb O; Nabulsi M
Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
[TBL] [Abstract][Full Text] [Related]
14. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice.
Winkler EA; Sengillo JD; Sagare AP; Zhao Z; Ma Q; Zuniga E; Wang Y; Zhong Z; Sullivan JS; Griffin JH; Cleveland DW; Zlokovic BV
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):E1035-42. PubMed ID: 24591593
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease.
Jaiswal MK
Neural Regen Res; 2017 May; 12(5):723-736. PubMed ID: 28616022
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease.
van der Burgh HK; Westeneng HJ; Meier JM; van Es MA; Veldink JH; Hendrikse J; van den Heuvel MP; van den Berg LH
Neuroimage Clin; 2019; 24():101984. PubMed ID: 31499409
[TBL] [Abstract][Full Text] [Related]
17. CSF markers in amyotrophic lateral sclerosis.
Tarasiuk J; KuĊakowska A; Drozdowski W; Kornhuber J; Lewczuk P
J Neural Transm (Vienna); 2012 Jul; 119(7):747-57. PubMed ID: 22555610
[TBL] [Abstract][Full Text] [Related]
18. The potential roles of aquaporin 4 in amyotrophic lateral sclerosis.
Zou S; Lan YL; Wang H; Zhang B; Sun YG
Neurol Sci; 2019 Aug; 40(8):1541-1549. PubMed ID: 30980198
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis.
Sasaki S
Neuropathology; 2015 Dec; 35(6):518-28. PubMed ID: 26242689
[TBL] [Abstract][Full Text] [Related]
20. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS.
Garbuzova-Davis S; Saporta S; Haller E; Kolomey I; Bennett SP; Potter H; Sanberg PR
PLoS One; 2007 Nov; 2(11):e1205. PubMed ID: 18030339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
